256 related articles for article (PubMed ID: 30919333)
21. Mitochondrial dysfunction in neurodegenerative diseases and cancer.
de Moura MB; dos Santos LS; Van Houten B
Environ Mol Mutagen; 2010 Jun; 51(5):391-405. PubMed ID: 20544881
[TBL] [Abstract][Full Text] [Related]
22. Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders.
Sas K; Robotka H; Toldi J; Vécsei L
J Neurol Sci; 2007 Jun; 257(1-2):221-39. PubMed ID: 17462670
[TBL] [Abstract][Full Text] [Related]
23. P2X7 Receptor and Purinergic Signaling: Orchestrating Mitochondrial Dysfunction in Neurodegenerative Diseases.
Zelentsova AS; Deykin AV; Soldatov VO; Ulezko AA; Borisova AY; Belyaeva VS; Skorkina MY; Angelova PR
eNeuro; 2022; 9(6):. PubMed ID: 36376084
[TBL] [Abstract][Full Text] [Related]
24. Mitochondrial Dysfunction Triggers Synaptic Deficits via Activation of p38 MAP Kinase Signaling in Differentiated Alzheimer's Disease Trans-Mitochondrial Cybrid Cells.
Yu Q; Du F; Douglas JT; Yu H; Yan SS; Yan SF
J Alzheimers Dis; 2017; 59(1):223-239. PubMed ID: 28598851
[TBL] [Abstract][Full Text] [Related]
25. Mitochondrial involvement in neurodegenerative diseases.
Zsurka G; Kunz WS
IUBMB Life; 2013 Mar; 65(3):263-72. PubMed ID: 23341346
[TBL] [Abstract][Full Text] [Related]
26. Melatonin: A Potential Anti-Oxidant Therapeutic Agent for Mitochondrial Dysfunctions and Related Disorders.
Ganie SA; Dar TA; Bhat AH; Dar KB; Anees S; Zargar MA; Masood A
Rejuvenation Res; 2016 Feb; 19(1):21-40. PubMed ID: 26087000
[TBL] [Abstract][Full Text] [Related]
27. Mitochondrial dysfunction in the development and progression of neurodegenerative diseases.
Johnson J; Mercado-Ayon E; Mercado-Ayon Y; Dong YN; Halawani S; Ngaba L; Lynch DR
Arch Biochem Biophys; 2021 May; 702():108698. PubMed ID: 33259796
[TBL] [Abstract][Full Text] [Related]
28. Improvement of neuronal bioenergetics by neurosteroids: implications for age-related neurodegenerative disorders.
Grimm A; Schmitt K; Lang UE; Mensah-Nyagan AG; Eckert A
Biochim Biophys Acta; 2014 Dec; 1842(12 Pt A):2427-38. PubMed ID: 25281013
[TBL] [Abstract][Full Text] [Related]
29. Mitochondrial defects in pancreatic beta-cell dysfunction and neurodegenerative diseases: Pathogenesis and therapeutic applications.
Onikanni SA; Lawal B; Oyinloye BE; Ajiboye BO; Ulziijargal S; Wang CH; Emran TB; Simal-Gandara J
Life Sci; 2023 Jan; 312():121247. PubMed ID: 36450327
[TBL] [Abstract][Full Text] [Related]
30. Metabolic reprogramming of human cells in response to oxidative stress: implications in the pathophysiology and therapy of mitochondrial diseases.
Wu YT; Wu SB; Wei YH
Curr Pharm Des; 2014; 20(35):5510-26. PubMed ID: 24606797
[TBL] [Abstract][Full Text] [Related]
31. Targeting cellular batteries for the therapy of neurological diseases.
Arora A; Behl T; Sehgal A; Singh S; Sharma N; Mathew B; Bungau S
Environ Sci Pollut Res Int; 2021 Aug; 28(31):41517-41532. PubMed ID: 34080116
[TBL] [Abstract][Full Text] [Related]
32. Mitochondrial iron metabolism and its role in neurodegeneration.
Horowitz MP; Greenamyre JT
J Alzheimers Dis; 2010; 20 Suppl 2(Suppl 2):S551-68. PubMed ID: 20463401
[TBL] [Abstract][Full Text] [Related]
33. Mitochondrial involvement in brain function and dysfunction: relevance to aging, neurodegenerative disorders and longevity.
Calabrese V; Scapagnini G; Giuffrida Stella AM; Bates TE; Clark JB
Neurochem Res; 2001 Jun; 26(6):739-64. PubMed ID: 11519733
[TBL] [Abstract][Full Text] [Related]
34. Mitochondrial trafficking and morphology in neuronal injury.
Rintoul GL; Reynolds IJ
Biochim Biophys Acta; 2010 Jan; 1802(1):143-50. PubMed ID: 19747973
[TBL] [Abstract][Full Text] [Related]
35. Targeting mitochondrial dysfunction in neurodegenerative disease: Part I.
Burchell VS; Gandhi S; Deas E; Wood NW; Abramov AY; Plun-Favreau H
Expert Opin Ther Targets; 2010 Apr; 14(4):369-85. PubMed ID: 20184395
[TBL] [Abstract][Full Text] [Related]
36. Mitochondriopathies as a Clue to Systemic Disorders-Analytical Tools and Mitigating Measures in Context of Predictive, Preventive, and Personalized (3P) Medicine.
Liskova A; Samec M; Koklesova L; Kudela E; Kubatka P; Golubnitschaja O
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670490
[TBL] [Abstract][Full Text] [Related]
37. Quercetin attenuates neuronal death against aluminum-induced neurodegeneration in the rat hippocampus.
Sharma DR; Wani WY; Sunkaria A; Kandimalla RJ; Sharma RK; Verma D; Bal A; Gill KD
Neuroscience; 2016 Jun; 324():163-76. PubMed ID: 26944603
[TBL] [Abstract][Full Text] [Related]
38. C. elegans as a model organism for human mitochondrial associated disorders.
Maglioni S; Ventura N
Mitochondrion; 2016 Sep; 30():117-25. PubMed ID: 26906059
[TBL] [Abstract][Full Text] [Related]
39. Mitochondria and the link between neuroinflammation and neurodegeneration.
Di Filippo M; Chiasserini D; Tozzi A; Picconi B; Calabresi P
J Alzheimers Dis; 2010; 20 Suppl 2():S369-79. PubMed ID: 20463396
[TBL] [Abstract][Full Text] [Related]
40. Antioxidative defense mechanisms controlled by Nrf2: state-of-the-art and clinical perspectives in neurodegenerative diseases.
Lim JL; Wilhelmus MM; de Vries HE; Drukarch B; Hoozemans JJ; van Horssen J
Arch Toxicol; 2014 Oct; 88(10):1773-86. PubMed ID: 25164826
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
